0 CHECKOUT

Biomarkers in Alzheimer's Disease - 2011

  • ID: 1574143
  • February 2011
  • Region: Global
  • 137 Pages
  • BioPharm Reports (VennBio Ltd.)

This report provides an overview of biomarkers associated with Alzheimer's disease (AD) that have potential in differential diagnosis, in following treatment, in clinical trials and drug discovery. These include molecules found in CSF and blood, genotypes, image-based parameters and others.

AD biomarkers offer utility in a number of ways: identification of groups at risk of developing AD; early detection of AD; differentiation of different forms of neurodegenerative disease from AD, as well as developmental stages (such as MCI), thought to progress to AD; supporting specific treatments or pharmacological interventions; following the time-course progression of AD and response to therapy; assessing patient prognosis; advancing understanding of the disease, including risk factors, and the changes that precede its development; the identification of new drug targets and candidate molecules; development of discovery assays for efficacy or toxicity markers; and supporting the recruitment of subjects most likely to provide a meaningful analysis of treatment effects. These areas are, therefore, considered and discussed in relation to the AD biomarkers presented in this report.

Of READ MORE >

Note: Product cover images may vary from those shown

Chapter 1 Background
1. Alzheimer's Disease
1.1 Statistics and Costs
1.2 Histopathology
1.3 Amyloid Beta (Abeta)
1.4 Tau Proteins and Neurofibrillary Tangles
1.5 Cholinergic Hypothesis
1.6 Diagnosis
1.7 Cognitive Tests
1.8 Stages of Alzheimer's Disease
1.9 Treatment of AD
1.10 Biomarkers
1.11 Genetics

Chapter 2 CSF Biomarkers and Diagnosis

Chapter 3 Blood Biomarkers and Diagnosis

Chapter 4 CSF Biomarkers and Early Detection

Chapter 5 Blood Biomarkers and Early Detection

Chapter 6 Genetic Biomarkers

Chapter 7 Image-Based Biomarkers

Chapter 8 Other Biomarkers

Chapter 9 Discussion

Tables

Table 2.1 CSF biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 3.1 Blood biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 4.1 CSF biomarkers associated with the diagnosis of early-stage Alzheimer's Disease
Table 5.1 Blood biomarkers associated with the diagnosis of early-stage Alzheimer's Disease
Table 6.1 Genetic biomarkers associated with Alzheimer's Disease
Table 7.1 Image-based biomarkers in Alzheimer's Disease
Table 8.1 Other biomarkers in Alzheimer's Disease
Table 9.1 Blood biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 9.2 Blood biomarkers associated with the detection of early-stage Alzheimer's Disease
Table 9.3 CSF biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 9.4. CSF biomarkers associated with the diagnosis of early-stage Alzheimer's Disease
Table 9.5 Genetic biomarkers associated with Alzheimer's Disease
Table 9.6 Image-based biomarkers In Alzheimer's Disease

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.